Physician profile
Patrick L Gomez
NPI 1972640134
$5,451.43
in general payments reported to CMS, 2019-2025
52 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $411 · 2021: $162 · 2022: $2,074 · 2023: $687 · 2024: $165 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.08 |
| Education | $319.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $448.66 | 2019-2023 | Venclexta, Lunsumio, Perjeta |
| Astrazeneca Pharmaceuticals LP | $446.11 | 2019-2025 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $370.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $347.42 | 2019-2023 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $328.33 | 2019-2025 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $307.83 | 2019-2022 | |
| Janssen Biotech, INC. | $303.98 | 2019-2023 | Erleada, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $296.09 | 2019-2023 | |
| Astellas Pharma US INC | $269.07 | 2019-2024 | Xospata, Vyloy |
| Pfizer INC. | $210.69 | 2019-2025 | |
| Genzyme Corporation | $137.62 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $128.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.34 | 2019-2023 | |
| Gilead Sciences, INC. | $117.60 | 2021-2023 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $107.20 | 2019-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.